Production (Stage)
Biocure Technology Inc.
CUREX
CNSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 11,650.00% | -97.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11,650.00% | -97.07% | |||
| Operating Income | -11,650.00% | 97.07% | |||
| Income Before Tax | -2,169.70% | 55.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2,169.70% | 55.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2,169.70% | 55.10% | |||
| EBIT | -11,650.00% | 97.07% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -14,200.00% | 93.75% | |||
| Normalized Basic EPS | -8,900.00% | 90.00% | |||
| EPS Diluted | -14,200.00% | 93.75% | |||
| Normalized Diluted EPS | -8,900.00% | 90.00% | |||
| Average Basic Shares Outstanding | -87.20% | 800.00% | |||
| Average Diluted Shares Outstanding | -87.20% | 800.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||